Triazole benzamide derivatives as GPR142 agonists

US11179371B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Armin Heckel · Biberach an der Riß, DE
• Robert AUGUSTIN · Ingelheim am Rhein, DE
• Sebastian Bandholtz · Schemmerhofen, DE
• Sara Frattini · Castelleone, IT
• Bernd Wellenzohn · Friedrichshafen, DE

Key dates

• Filing date: Jun 28, 2019
• Grant date: Nov 23, 2021
• Expiry date: Jun 28, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.